Cargando…

Identification of Ten Mitosis Genes Associated with Tamoxifen Resistance in Breast Cancer

BACKGROUND: Endocrine therapy is the backbone therapy in estrogen receptor α (ER)-positive breast cancer, and tamoxifen resistance is a great challenge for endocrine therapy. Tamoxifen-resistant and sensitive samples from the international public repository, the Gene Expression Omnibus (GEO) databas...

Descripción completa

Detalles Bibliográficos
Autores principales:	Sun, Xi, Ding, Shuning, Lu, Shuangshuang, Wang, Zheng, Chen, Xiaosong, Shen, Kunwei
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Dove 2021
Materias:	Original Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8187086/ https://www.ncbi.nlm.nih.gov/pubmed/34113127 http://dx.doi.org/10.2147/OTT.S290426

Ejemplares similares

Association of molecular subtype concordance and survival outcome in synchronous and metachronous bilateral breast cancer
por: Ding, Shuning, et al.
Publicado: (2021)

A novel metabolic gene signature-based nomogram to predict overall survival in breast cancer
por: Sun, Xi, et al.
Publicado: (2021)

Single‐cell RNA sequencing in breast cancer: Understanding tumor heterogeneity and paving roads to individualized therapy
por: Ding, Shuning, et al.
Publicado: (2020)

Identification and characterization of critical genes associated with tamoxifen resistance in breast cancer
por: Zhang, Kai, et al.
Publicado: (2020)

Long Noncoding RNA Signature and Disease Outcome in Estrogen Receptor-Positive Breast Cancer Patients Treated with Tamoxifen
por: Wang, Gen, et al.
Publicado: (2018)

CRISPR-cas9 Screening Identified Lethal Genes Enriched in Cell Cycle Pathway and of Prognosis Significance in Breast Cancer
por: Sun, Xi, et al.
Publicado: (2021)

Luminal Breast Cancer Cell Lines Overexpressing ZNF703 Are Resistant to Tamoxifen through Activation of Akt/mTOR Signaling
por: Zhang, Xi, et al.
Publicado: (2013)

Resuming Sensitivity of Tamoxifen-Resistant Breast Cancer Cells to Tamoxifen by Tetrandrine
por: Wang, Yuntao, et al.
Publicado: (2021)

Curcumin Induces Cell Death and Restores Tamoxifen Sensitivity in the Antiestrogen-Resistant Breast Cancer Cell Lines MCF-7/LCC2 and MCF-7/LCC9
por: Jiang, Min, et al.
Publicado: (2013)

A prospective, randomized study of Toremifene vs. tamoxifen for the treatment of premenopausal breast cancer: safety and genital symptom analysis
por: Hong, Jin, et al.
Publicado: (2020)

Identification of potential target genes of honokiol in overcoming breast cancer resistance to tamoxifen
por: Hermawan, Adam, et al.
Publicado: (2022)

Single‐cell atlas reveals a distinct immune profile fostered by T cell‐B cell crosstalk in triple negative breast cancer
por: Ding, Shuning, et al.
Publicado: (2023)

Identification of key genes involved in tamoxifen-resistant breast cancer using bioinformatics analysis
por: Wang, Xiaopeng, et al.
Publicado: (2021)

Tamoxifen Resistance in Breast Cancer
por: Chang, Minsun
Publicado: (2012)

Association of Biomarker Discrepancy and Treatment Decision, Disease Outcome in Recurrent/Metastatic Breast Cancer Patients
por: Lu, Yujie, et al.
Publicado: (2021)

A large-cohort retrospective study of metastatic patterns and prognostic outcomes between inflammatory and non-inflammatory breast cancer
por: Wang, Zheng, et al.
Publicado: (2020)

Metabolic Syndrome and Breast Cancer: Prevalence, Treatment Response, and Prognosis
por: Dong, Shuwen, et al.
Publicado: (2021)

Breast Subtypes and Prognosis of Breast Cancer Patients With Initial Bone Metastasis: A Population-Based Study
por: Liu, Deyue, et al.
Publicado: (2020)

Comprehensive analysis of the 21-gene recurrence score in invasive ductal breast carcinoma with or without ductal carcinoma in situ component
por: Zeng, Yufei, et al.
Publicado: (2020)

The Comparative Safety of Epirubicin and Cyclophosphamide versus Docetaxel and Cyclophosphamide in Lymph Node-Negative, HR-Positive, HER2-Negative Breast Cancer (ELEGANT): A Randomized Trial
por: Liu, Deyue, et al.
Publicado: (2022)

MicroRNA-320a sensitizes tamoxifen-resistant breast cancer cells to tamoxifen by targeting ARPP-19 and ERRγ*
por: Lü, Mingrong, et al.
Publicado: (2015)

Association of Ki-67 Change Pattern After Core Needle Biopsy and Prognosis in HR+/HER2− Early Breast Cancer Patients
por: Li, Shuai, et al.
Publicado: (2022)

Inhibition of histone deacetylases attenuates tumor progression and improves immunotherapy in breast cancer
por: Lian, Bi, et al.
Publicado: (2023)

Association of serum lipid levels and clinical outcomes in early breast cancer patients
por: Dong, Shuwen, et al.
Publicado: (2023)

Identification of a Putative Protein Profile Associated with Tamoxifen Therapy Resistance in Breast Cancer
por: Umar, Arzu, et al.
Publicado: (2009)

21-Gene Recurrence Assay Associated With Favorable Metabolic Profiles in HR-Positive, HER2-Negative Early-Stage Breast Cancer Patients
por: Zhu, Yifei, et al.
Publicado: (2021)

Identification of MAGEA antigens as causal players in the development of tamoxifen-resistant breast cancer
por: Wong, P-P, et al.
Publicado: (2014)

Identification of Tamoxifen-Resistant Breast Cancer Cell Lines and Drug Response Signature
por: Guan, Qingzhou, et al.
Publicado: (2020)

Association of tamoxifen resistance and lipid reprogramming in breast cancer
por: Hultsch, Susanne, et al.
Publicado: (2018)

Inhibition of STAT3 enhances sensitivity to tamoxifen in tamoxifen-resistant breast cancer cells
por: Moon, Seo Yun, et al.
Publicado: (2021)

Molecular prediction of tamoxifen resistance in breast cancer
por: Kok, M, et al.
Publicado: (2005)

Diverse Distribution and Gene Expression on the 21-Gene Recurrence Assay in Breast Cancer Patients with Locoregional Recurrence Versus Distant Metastasis
por: Lu, Yujie, et al.
Publicado: (2021)

Decision-making of Adjuvant Chemotherapy for Breast Cancer Patients with Discordant Risk Classifications between Clinical-Pathological Factors and 21-gene Recurrence Score
por: Gao, Weiqi, et al.
Publicado: (2020)

An epigenomic approach to therapy for tamoxifen-resistant breast cancer
por: Feng, Qin, et al.
Publicado: (2014)

Impact of Prior Cancer History on the Clinical Outcomes in Advanced Breast Cancer: A Propensity Score–Adjusted, Population-Based Study
por: Lin, Caijin, et al.
Publicado: (2020)

Weight Gain during Neoadjuvant Chemotherapy is Associated with Worse Outcome among the Patients with Operable Breast Cancer
por: Fang, Qiong, et al.
Publicado: (2019)

Transcriptome profiling identified differentially expressed genes and pathways associated with tamoxifen resistance in human breast cancer
por: Men, Xin, et al.
Publicado: (2017)

Identification and targeting of selective vulnerability rendered by tamoxifen resistance
por: Singh, Madhurendra, et al.
Publicado: (2020)

Transcriptional coregualtor NUPR1 maintains tamoxifen resistance in breast cancer cells
por: Wang, Lingling, et al.
Publicado: (2021)

Prognostic Factors and Surgery for Breast Cancer Patients With Locoregional Recurrence: An Analysis of 5,202 Consecutive Patients
por: Huang, Jiahui, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_9cstbarckor43jadl7t1va6nej